Oragenics gets NYSE American deficiency notice, updates trial and FDA progress
Oragenics disclosed a stockholders' equity shortfall triggering a listing compliance deadline, alongside continued Phase IIa dosing for ONP-002 and an ongoing FDA review of its Type B meeting package.
SEC filing